Aldehyde Acetal Intermediates for Macrocyclic Depsipeptide Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing macrocyclic depsipeptides, such as those used in treating inflammatory and hyperproliferative skin diseases, face challenges with low yield and instability of intermediates, particularly the aldehyde intermediate in forming the ahp-substructure, which complicates the synthesis and increases the risk of side reactions.
Innovation Solution
The use of the 5-oxo-analogue of 2-amino-5-hydroxypentanoic acid in acetal form instead of the precursor, combined with solid phase peptide synthesis and solution phase reactions, allows for the production of cyclic depsipeptides with improved yield and purity by avoiding the oxidation step and using N-Me-Tyrosine instead of protected variants, thereby reducing by-products and simplifying the process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If oxidation of 2-amino-5-hydroxypentanoic acid is used to form the ahp-substructure, then the macrocyclic depsipeptide can be synthesized, but the aldehyde intermediate is too unstable to be isolated and the yield is low
Solution Approach 1:
The patent uses an acetal derivative as a stable intermediary to replace the unstable aldehyde intermediate. The acetal form (1,3-dioxolane ring) serves as a mediator that can be isolated and handled, then converted to the desired ahp-substructure through hydrolysis, thereby solving the instability problem while maintaining synthesis feasibility
Solution Approach 2:
The patent changes the chemical form of the intermediate from aldehyde to acetal by modifying the protecting group. This parameter change transforms the unstable aldehyde into a stable acetal derivative that can be isolated and manipulated, then converted back to the aldehyde functionality needed for ahp-substructure formation through controlled hydrolysis
2Stability of the object's composition
If acetal protecting groups are used to stabilize the aldehyde intermediate, then the intermediate becomes isolable, but the acetal is unstable under acidic conditions and may decompose
Solution Approach 1:
The patent performs preliminary protection of the aldehyde as an acetal before any acid-sensitive steps. The acetal is introduced in a stable form, and acid-sensitive operations are performed before final deprotection. This timing strategy allows the acetal to serve its stabilizing function while avoiding conditions that would cause decomposition
Solution Approach 2:
The patent skips the problematic acid-catalyzed steps during the synthesis phase by using the stable acetal form. The acetal is carried through base-mediated reactions and other non-acidic steps, and only converted to the aldehyde form just before the final cyclization step, thereby avoiding exposure to harmful acidic conditions throughout the synthesis
3Productivity
If traditional solution chemistry approaches are used for synthesis, then the process can be completed, but the number of steps is high and handling is difficult
Solution Approach 1:
The patent segments the synthesis process into two distinct phases: solid phase peptide synthesis for the linear precursor (simplifying handling and reducing steps) and solution phase cyclization for the final macrocycle formation. This segmentation allows each phase to be optimized independently, reducing overall complexity while maintaining yield
Solution Approach 2:
The patent uses solid phase synthesis as a simplified copy of the final solution phase process. By building the linear precursor on solid support using standardized coupling reactions, the complex solution-phase step-by-step assembly is replaced with a more efficient solid-phase approach, reducing the number of steps and improving handling
4Ease of manufacture
If protected variants such as t-butyl-ethers are used instead of N-Me-Tyrosine, then the synthesis can proceed, but the protected variants are expensive and difficult to prepare
Solution Approach 1:
Instead of using expensive protected variants and removing them later, the patent inverts the approach by using N-Me-Tyrosine as the final, deprotected amino acid building block from the start. This eliminates the need for expensive protected variants like t-butyl-ethers, simplifying both the synthesis process and material requirements while maintaining the desired chemical functionality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the yield and stereoisomeric purity of cyclic depsipeptides, reduces the number of synthesis steps, and stabilizes the acetal protecting groups, making the process more efficient and manageable, while eliminating the need for expensive and difficult-to-prepare protected variants.
Implementation Method 1
use its 5-oxo-analogue in acetal form instead
Implementation Method 2
oxidation of the open chain precursor amino acid 2-amino-5-hydroxy-pentanoic acid in the closed macrolactone ring by oxidative treatment
Data Source
AI summary
The invention relates to a method or process for the chemical manufacture of depsipeptides of the formula I employing an aldehyde acetal intermediate,wherein the symbols have the meaning defined in the description, to new intermediates and their manufacture, as well as related invention embodiments.